5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Dyer, M.; May, J. R.; Ejzykowicz, F.; Kurt, M.; Lee, C. W.; Wang, P.; Testa, E.; Sharpe, D. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
    Meeting Abstract

    Thouvenin, J.; Alhalabi, O.; Carlo, M.; Ajuria, L. C.; Bakouny, Z.; Chanza, N. M.; Negrier, S.; Campedel, L.; Bilen, M. A.; Borchiellini, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
    Meeting Abstract

    Linch, M.; Liu, G.; Crabb, S. J.; Beer, T. M.; Heath, E.; Gordon, M.; de Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Custodio, J. M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Meeting Abstract

    Albiges, L.; Gurney, H. P.; Atduev, V.; Suarez, C.; Duran, M. A. C.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Gupta, S.; Yang, Q.; Halabi, S.; Tubbs, A.; Gore, Y.; George, D. J.; Nanus, D. M.; Antonarakis, E. S.; Danila, D.; Szmulewitz, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
    Meeting Abstract

    Morris, M. J.; de Bono, J. S.; Nagarajah, J.; Wei, X. X.; Nordquist, L. T.; Koshkin, V. S.; Vickers, A.; Mirante, O.; Ghouse, R.; Tagawa, S. T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Xie, W.; Carducci, M. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial
    Meeting Abstract

    Armstrong, A. J.; Sartor, O.; Saad, F.; Czernin, J.; Shore, N. D.; Kendi, A. T.; Beer, T. M.; Vaishampayan, N.; El-Haddad, G.; Wu, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial
    Meeting Abstract

    Friedman, C. F.; D'Souza, A. A.; Tinker, A. V.; Corral, E.; Gambardella, V.; Goldman, J. W.; Loi, S.; Melisko, M.; Oaknin, A.; Spanggaard, I.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save